Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug is a premedication solution used primarily to improve mucosal visibility during upper gastrointestinal endoscopy (gastroscopy). It consists of simethicone, an anti-foaming agent that reduces gas bubbles; acetylcysteine, a mucolytic agent that degrades mucus by breaking disulfide bonds; and sodium bicarbonate, which acts as a pH regulator to optimize the mucolytic activity of acetylcysteine and neutralize gastric acid. Developed by researchers at Beijing Friendship Hospital and Capital Medical University, the solution is administered orally shortly before the procedure to clear the gastric field of foam and secretions, thereby enhancing the detection of lesions such as early gastric cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on simethicone + acetylcysteine + sodium bicarbonate.